Basic Information
Inaqovi
Regulatory Information
EMEA/H/C/005823
Authorised
September 15, 2023
July 20, 2023
3
November 30, 2023
Company Information
Netherlands
Herikerbergweg 292 1101 CT Amsterdam
Otsuka Pharmaceutical Netherlands B.V.
Drug Classification
Additional Monitoring
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Inaqovi is indicated as monotherapy for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) who are ineligible for standard induction chemotherapy.
Overview Summary
Inaqovi is a cancer medicine used in adults to treat newly diagnosed acute myeloid leukaemia (AML), a type of cancer affecting the white blood cells. It is used in patients who are not eligible for standard induction chemotherapy (initial treatment with cancer medicines). Inaqovi contains two active substances, decitabine and cedazuridine.